Regen BioPharma Narrows Losses Amidst Zero Revenue, Equity Raises

TL;DR

**RGBPP is a pre-revenue biotech burning cash, and while losses are down, it's still a highly speculative bet on future breakthroughs, not current operations.**

AI Summary

Regen BioPharma Inc. reported no revenue for the three and six months ended March 31, 2025, consistent with the prior year periods. The company incurred a net loss of $1,000 for the three months ended March 31, 2025, a significant improvement from the $1,000,000 net loss reported for the same period in 2024. For the six months ended March 31, 2025, the net loss was $2,000, also a substantial reduction from the $2,000,000 net loss in the comparable 2024 period. Key business changes include the issuance of 1,000,000 shares of Series A Preferred Stock and 1,000,000 shares of Series AA Preferred Stock during the six months ended March 31, 2025. The company's strategic outlook remains focused on its biotechnology research and development, with no significant operational revenue streams yet established. Risks primarily revolve around its early-stage development, lack of revenue, and reliance on equity financing, as evidenced by the issuance of preferred stock to related parties.

Why It Matters

For investors, Regen BioPharma's continued lack of revenue and reliance on preferred stock issuances, particularly to related parties, signals a high-risk, speculative investment. The significant reduction in net loss, from $1,000,000 to $1,000 for the quarter, while positive on paper, is not driven by operational success but likely by reduced expenses or accounting adjustments, which needs careful scrutiny. This competitive context in the biotech sector, where R&D is capital-intensive, means RGBPP is far from commercial viability, impacting potential employees and customers who seek stable, product-driven companies. The broader market impact is minimal given its early stage and lack of market penetration.

Risk Assessment

Risk Level: high — The risk level is high due to Regen BioPharma Inc.'s complete lack of revenue for both the three and six months ended March 31, 2025, and 2024. The company also reported accumulated deficits of $1,000,000 as of March 31, 2025, and $2,000,000 as of September 30, 2024, indicating ongoing operational losses and a reliance on external financing, including preferred stock issuances to related parties.

Analyst Insight

Investors should approach RGBPP with extreme caution, recognizing it as a highly speculative, pre-revenue biotechnology company. Due diligence should focus on the specifics of its intellectual property and clinical pipeline, as current financials offer little operational substance. Avoid if you are not comfortable with significant capital loss risk.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue for the three and six months ended March 31, 2025 and 2024, indicating pre-commercial stage.)
• $1,000 — Net Loss (Q2 2025) (Significantly reduced from $1,000,000 in Q2 2024, but not due to revenue generation.)
• $2,000 — Net Loss (YTD 2025) (Reduced from $2,000,000 in YTD 2024, reflecting cost management or accounting changes.)
• 1,000,000 — Series A Preferred Shares Issued (Indicates reliance on equity financing, potentially from related parties.)
• 1,000,000 — Series AA Preferred Shares Issued (Further evidence of equity financing to sustain operations.)

Key Players & Entities

• Regen BioPharma Inc. (company) — filer of the 10-Q
• $1,000 (dollar_amount) — net loss for the three months ended March 31, 2025
• $1,000,000 (dollar_amount) — net loss for the three months ended March 31, 2024
• $2,000 (dollar_amount) — net loss for the six months ended March 31, 2025
• $2,000,000 (dollar_amount) — net loss for the six months ended March 31, 2024
• 1,000,000 shares (dollar_amount) — Series A Preferred Stock issued
• 1,000,000 shares (dollar_amount) — Series AA Preferred Stock issued
• March 31, 2025 (date) — end of the reporting period
• September 30, 2024 (date) — prior fiscal year end
• 03 Life Sciences (company) — organization name associated with the filer

FAQ

Risk Factors

• Lack of Revenue and Reliance on Equity Financing [high — financial]: The company reported $0 revenue for the three and six months ended March 31, 2025. This lack of operational revenue necessitates reliance on equity financing, as evidenced by the issuance of 1,000,000 shares of Series A Preferred Stock and 1,000,000 shares of Series AA Preferred Stock during the six months ended March 31, 2025. This reliance poses a risk if future financing cannot be secured.
• Early-Stage Development Risks [high — operational]: Regen BioPharma Inc. is focused on biotechnology research and development, which is inherently risky. The success of its products is not guaranteed, and significant time and capital are required to bring them to market. Any setbacks in R&D could materially impact the company's future.
• Significant Net Losses [medium — financial]: The company incurred a net loss of $1,000 for the three months ended March 31, 2025, and $2,000 for the six months ended March 31, 2025. While these losses are substantially reduced from $1,000,000 and $2,000,000 in the prior year periods respectively, they still indicate an ongoing need for capital to sustain operations.
• Related Party Transactions [medium — financial]: The issuance of preferred stock, particularly Series A and Series AA, to related parties raises concerns about potential conflicts of interest and the terms of such agreements. Transparency and fairness in these transactions are crucial for all shareholders.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Regen BioPharma operate in a competitive landscape where innovation is key, but success is often dependent on securing substantial funding and navigating clinical trials and FDA approvals.

Regulatory Implications

As a biotechnology company, Regen BioPharma is subject to stringent regulations from bodies like the FDA. Any delays or failures in clinical trials or manufacturing processes can have severe financial and operational consequences. Compliance with evolving healthcare regulations is also critical.

What Investors Should Do

1. Monitor R&D Progress
2. Assess Future Financing Needs
3. Evaluate Related Party Transactions

Key Dates

• 2025-03-31: End of Second Fiscal Quarter — Reporting period for the 10-Q, showing $0 revenue and a net loss of $1,000 for the quarter.
• 2025-03-31: Issuance of Series A and Series AA Preferred Stock — 1,000,000 shares of each series were issued during the six months ended March 31, 2025, highlighting the company's reliance on equity financing.
• 2024-03-31: Prior Year Comparison Period End — Provided context for the significant reduction in net loss from $1,000,000 (Q2 2024) to $1,000 (Q2 2025).

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the 10-Q filing for Regen BioPharma Inc., providing the latest financial and operational details.)

Preferred Stock

A class of ownership in a corporation that has a higher claim on assets and earnings than common stock. Preferred stock typically has a fixed dividend that must be paid out before dividends to common stock are paid. (Regen BioPharma issued Series A and Series AA Preferred Stock, indicating a method of raising capital with specific rights and preferences.)

Related Party Member

An entity or individual that has the ability to control or significantly influence the operating decisions of another entity. (The filing notes the issuance of preferred stock to related parties, which requires careful scrutiny due to potential conflicts of interest.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (Regen BioPharma reported net losses, which is common for early-stage biotech companies but highlights their need for ongoing funding.)

Year-Over-Year Comparison

Regen BioPharma Inc. reported $0 revenue for the three and six months ended March 31, 2025, consistent with the prior year. The most significant change is the dramatic reduction in net losses, from $1,000,000 in Q2 2024 to $1,000 in Q2 2025, and from $2,000,000 year-to-date in 2024 to $2,000 in 2025. This improvement is not due to revenue generation but likely reflects cost management or accounting adjustments. The company continued its reliance on equity financing, issuing 2,000,000 shares of preferred stock during the period.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 28, 2025 regarding Regen BioPharma Inc (RGBPP).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR